Marchegiani Giovanni, Mino-Kenudson Mari, Ferrone Cristina R, Morales-Oyarvide Vicente, Warshaw Andrew L, Lillemoe Keith D, Castillo Carlos Fernández-Del
*Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA †Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Ann Surg. 2015 Dec;262(6):1108-14. doi: 10.1097/SLA.0000000000001008.
To describe the patterns of recurrence after resection of intraductal papillary mucinous neoplasms (IPMN) of the pancreas.
IPMNs represent an increasing indication for pancreatic resection, but little is known about the actual incidence and the patterns of recurrence after surgical excision.
Retrospective review of 412 resected IPMNs from 1990 to 2013 who have had near-complete follow-up.
Median age of the cohort was 68 years, 56% had branch duct (BD)-IPMN and 21% had invasive cancers. Nineteen patients (5%) had distinct pancreatic ductal adenocarcinoma (PDAC) and were excluded from the recurrence analysis. After a median of 58 months, 65 of 381 patients (17%) experienced recurrence of the IPMN, and 5- and 10-year disease-free survival (DFS) was 82% and 78%, respectively. Only 2 patients (0.5%) developed metachronous PDAC. In 33 patients (9%), a residual BD-IPMN was left in the pancreatic remnant, but none of these significantly grew or required reoperation. Invasive component and resection margin positive for IPMN were predictors of recurrence (P < 0.05). Invasive IPMN recurred in 45% of cases, whereas noninvasive in only 9% and later (P < 0.001), but patterns depended on IPMN subtypes. Only 9 patients required reoperation for recurrence, with good long-term outcome particularly for oncocytic IPMNs.
Recurrence of noninvasive BD-IPMN is infrequent and surveillance may be avoided in selected cases. In invasive IPMN recurrence depends on N status, pancreatic margin, and invasive type.
描述胰腺导管内乳头状黏液性肿瘤(IPMN)切除术后的复发模式。
IPMN越来越多地成为胰腺切除术的适应证,但对于手术切除后的实际发病率和复发模式知之甚少。
回顾性分析1990年至2013年412例接受切除且随访接近完整的IPMN患者。
该队列患者的中位年龄为68岁,56%为分支导管(BD)-IPMN,21%为浸润性癌。19例(5%)患者患有明确的胰腺导管腺癌(PDAC),被排除在复发分析之外。中位随访58个月后,381例患者中有65例(17%)出现IPMN复发,5年和10年无病生存率(DFS)分别为82%和78%。仅2例(0.5%)患者发生异时性PDAC。33例(9%)患者的胰腺残端残留有BD-IPMN,但均未显著生长或需要再次手术。IPMN的浸润成分和切缘阳性是复发的预测因素(P<0.05)。浸润性IPMN的复发率为45%,而非浸润性IPMN仅为9%且复发较晚(P<0.001),但复发模式取决于IPMN亚型。仅9例患者因复发需要再次手术,长期预后良好,尤其是嗜酸性细胞性IPMN。
非浸润性BD-IPMN复发罕见,部分病例可避免监测。浸润性IPMN的复发取决于N状态、胰腺切缘和浸润类型。